Clinical trials: Body Dysmorphic Disorder
Body Dysmorphic Disorder, Obsessive-Compulsive Spectrum Disorder
Cognitive-Behavioral Therapy and Supportive Psychotherapy for Body Dysmorphic Disorder
The purpose of this study is to learn more about two different types of psychotherapy to help individuals who have body dysmorphic disorder (BDD).
- Conditions
- Body Dysmorphic Disorder, Obsessive-Compulsive Spectrum Disorder, Anxiety Disorders, Somatoform Disorders
- Trial name
- NCT01453439
- Testing
- Cognitive Behavioral Therapy, Supportive Psychotherapy
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Massachusetts General Hospital
Body Dysmorphic Disorder
Fluoxetine in Pediatric Body Dysmorphic Disorder
This trial will study the effectiveness of the medication fluoxetine for children and adolescents ages 16 and younger with BDD who qualify.
- Trial name
- FDA BDD (NCT00245635)
- Testing
- Fluoxetine
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Montefiore Medical Center
Inflammatory Bowel Diseases, Depressive Episode
Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
This study is a large population-based analysis in the United Kingdom (UK) using routine primary care data to investigate the impacts on quality-of-life outcomes and use of healthcare services in people aged 5 - 25 years…
- Conditions
- Inflammatory Bowel Diseases, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorder
- Trial name
- NCT05206734
- Testing
- No specific intervention
- Where
- United Kingdom
- Volunteers
- 19,469 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Body Dysmorphic Disorders
Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder
In this pilot study 12 adult outpatients with body dysmorphic disorder that has not responded to at least one adequate trial of a serotonin reuptake inhibitor will be treated openly with a single oral dose of psilocybin.
- Trial name
- NCT04656301
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- New York State Psychiatric Institute
Body Dysmorphic Disorder, Obsessive-compulsive Disorder
Oxytocin Administration in BDD and OCD
The purpose of the current study is to investigate the effect of an acute administration of intranasal oxytocin, relative to placebo, on social cognitive impairments among individuals with body dysmorphic disorder and…
- Trial name
- NCT02671266
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Body Dysmorphic Disorder
Cognitive Behaviour Therapy (CBT) for Body Dysmorphic Disorder (BDD)
The aim of the research is to determine if Cognitive Behaviour Therapy (CBT) specific for BDD is more effective than a credible non-specific form of CBT for treating BDD and its delusional variant in adults aged 17 or over.
- Trial name
- NCT00871143
- Testing
- CBT specific for BDD, Non specific CBT
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- Institute of Psychiatry, London
Body Dysmorphic Disorder
D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder
The purpose of the study is to conduct a double-blind, placebo-controlled study of D-cycloserine (DCS) augmentation of behavior therapy in individuals with Body Dysmorphic Disorder (BDD).
- Trial name
- BDD/DCS (NCT00842309)
- Testing
- d-cycloserine
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Massachusetts General Hospital
Body Dysmorphic Disorders
Smartphone-Administered App Treatment for Adults With Body Dysmorphic Disorder
The investigators are developing and testing a Smartphone-based cognitive behavioral therapy (CBT) "app" for body dysmorphic disorder (BDD).
- Trial name
- NCT03221738
- Testing
- App-Based Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Bulimia Nervosa, Body Dysmorphic Disorder
An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder
The primary objective of this 13-week clinical trial is to test the hypothesis that treatment with Memantine will significantly improve the symptoms of those suffering from either bulimia nervosa, purging type or suffering from…
- Trial name
- NCT01038128
- Testing
- Memantine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Mclean Hospital
Body Dysmorphic Disorder
Waitlist-Control Trial of Smartphone Cognitive Behavioral Therapy (CBT) for Body Dysmorphic Disorder (BDD)
The investigators are testing the efficacy of Smartphone-delivered cognitive behavioral therapy (CBT) treatment for body dysmorphic disorder (BDD).
- Trial name
- NCT03673046
- Testing
- Smartphone-delivered cognitive behavioral therapy (CBT) for body dysmorphic disorder (BDD)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Massachusetts General Hospital
Body Dysmorphic Disorder
Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder
The purpose of this study is to assess the usefulness of a medication (Levetiracetam) for people with body dysmorphic disorder.
- Trial name
- NCT00265109
- Testing
- Levetiracetam
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Butler Hospital
Anxiety Disorders, Somatoform Disorders
Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder
This study's primary aim is to compare time to relapse and relapse rates in responders to acute escitalopram who are then randomized to placebo versus continuation treatment with escitalopram.
- Trial name
- NCT00149799
- Testing
- Escitalopram
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Body Dysmorphic Disorder
CBT as an Adjunct to SRIs in the Treatment of BDD
The research project is a controlled pilot study of the efficacy of cognitive-behavioral therapy (CBT) as an adjunct to serotonin reuptake inhibitor (SRI) pharmacotherapy in body dysmorphic disorder (BDD).
- Trial name
- NCT00211809
- Testing
- Cognitive Behavioral Therapy, Venlafaxine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Icahn School of Medicine at Mount Sinai